爱普股份拟收购挪亚圣诺生物科技,股价近期震荡下行

Group 1 - The core point of the article is that Aipu Co., Ltd. plans to acquire 100% equity of Noah Sanno (Taicang) Biotechnology Co., Ltd. for no less than 450 million yuan, with the first step involving the purchase of 80% equity for a tentative price of 360 million yuan [1] - The acquisition is structured in two phases, with the remaining 20% equity to be delivered after a performance commitment period from 2026 to 2028, where the seller guarantees a cumulative net profit of no less than 150 million yuan [1] - The agreement is preliminary and non-binding, meaning the final transaction is subject to due diligence and carries uncertainties [1] Group 2 - In the recent trading period from February 6 to February 12, 2026, Aipu's stock price has shown a downward trend, closing at 10.85 yuan on February 12, down 6.47% from 11.44 yuan on February 6 [2] - The stock experienced a trading range of 8.28%, with a low of 10.82 yuan on February 12, and a single-day decline of 1.81% on that date, with a turnover rate of 1.13% and a trading volume of 47.3 million yuan [2] - Technical analysis indicates that the stock is underperforming compared to the market and industry, with short-term resistance at 11.59 yuan and support at 10.49 yuan [2] Group 3 - Institutional sentiment is neutral, with no clear bullish or bearish ratings at this time [3] - One institution forecasts a net profit of 160 million yuan for 2025, representing a year-on-year growth of 16.79%, and a net profit of 182 million yuan for 2026, reflecting a year-on-year growth of 13.75% [3] - The current price-to-earnings ratio (TTM) is 22.81 times, and the price-to-book ratio is 1.26 times [3]